PreOmics Exit
PreOmics develops and provides innovative technologies for customers around the world for mass spectrometry (MS) - based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.
Press releases
Press
PreOmics Announces Early Investors’ Exit and Closing of Series B Financing to Accelerate R&D and Commercialization of Proteomics Tools and Consumables
PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance Consumables for the Homogenization, Enrichment and Proteomic Sample Preparation of Biopsy, Tissue, Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Pharmaceutical and Clinical Research
MUNICH, Germany – January 18, 2022 – PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis
Press
High-Tech Gründerfonds and Think.Health Ventures together with Business Angels invest 3.3 million euros in a series A for the growth of PreOmics in Martinsried, Germany
PreOmics develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry. Today, the processing of samples for mass spectrometry is usually carried out according to homemade protocols. These processes are slow, not reproducible, not robust and cannot be automated. These solutions are therefore very time-consuming and costly, which can lead to the loss of valuable samples.
PreOmics addresses these problems with a standardized technology that enables robust
Info & Contact
Address
PreOmics GmbH
Am Klopferspitz 19
D-82152 Planegg/Martinsried
Am Klopferspitz 19
D-82152 Planegg/Martinsried
In portfolio
06. Feb 2017 – 18. Jan 2022
Sector
Exit